10.IMMUNOHISTOCHEMICAL EXPRESSION OF CD133 IN OVARIAN SURFACE EPITHELIAL TUMORS

Background: The identification of antigenic profile of the cancer stem cells might have relevant clinical implication as they're able to proliferate and self-renew, in turn sustaining tumor growth. CD133 is one of robust surface marker for cancer stem cells in various neoplastic human tissues, including ovaries. It is associated with the clinical outcome of patients.
Objective: To assess the immunohistochemichal expression of cancer stem cell marker (CD133) in ovarian surface epithelial tumors.
Methods: This study included a total of 100 ovarian tissue paraffin blocks, 70 tissue paraffin blocks included ovarian tumors obtained from patient who underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy, while 30 tissue paraffin blocks assigned as the control group included normal ovarian tissue and fallopian tubes tissue. From each paraffin block, 2 sections were taken, one was stained with hematoxylin and eosin stain and the other section was stained immunohistochemically for CD133.
Results: CD133 showed a high significant difference in its immunohistochemical expression between the control group and the case groups with the highest expression seen in malignant ovarian surface epithelial tumors (P < 0.001). CD133 expression was highly significantly associated with histopathological type (P < 0.001). CD133 also showed a significant relation to age (r = 0.254, P= 0.034), tumor grade (r = 0.794, P < 0.001), tumor stage (r = 0.543, P= 0.013) and presence of ascites (P < 0.001).
Conclusion: CD133 expression revealed a highly significant differences in the ovarian surface epithelial tumors tissues compared to control group, which reflect its important role in ovarian carcinogenesis.
Keywords: Ovarian surface epithelial tumors, ovarian carcinoma, cancer stem cells, cancer stem cell marker, CD133, immunohistochemistry
Citation: Al-Shami SA, Qasim BJ, Hassan AM. Immunohistochemical expression of CD133 in ovarian surface epithelial tumors. Iraqi JMS. 2018; 16(3): 308-318. doi: 10.22578/IJMS.16.3.10